Zhongchao Inc. (ZCMD): Business Model Canvas [Dec-2025 Updated]

You're looking for a clear, no-fluff breakdown of Zhongchao Inc.'s (ZCMD) business model as of late 2025, and honestly, the numbers tell a story of a company facing a tough near-term reality. We've mapped out their nine building blocks-from their key partnerships with pharma giants and the China Health Promotion Association (CHPA) to their reliance on the MDMOOC digital education platform-but the real focus right now has to be the financials: H1 2025 revenue clocked in at just $5.6 million, a sharp drop, while they're burning cash at an estimated $4.5 million annually. This canvas shows exactly where the value is supposed to come from, but it also clearly highlights the pressure points in their cost structure and revenue streams that need immediate attention; dive into the details below to see the full strategic picture.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Key Partnerships

You're looking at the structure of Zhongchao Inc. (ZCMD)'s alliances, which are critical for delivering its professional training and patient management services. These partnerships provide the necessary access to experts, distribution channels, and patient support infrastructure.

The company relies on established relationships with major industry players to execute its service offerings. For instance, the collaboration with a major pharmaceutical company like Takeda Pharmaceutical, expanded in November $\text{2020}$, covers services across five of Takeda's Chinese subsidiaries, including medical editing and professional training programs.

Zhongchao Inc. (ZCMD) maintains specific, measurable engagements that define the scale of its partnership impact:

• The Pulmonary Arterial Hypertension Online Course, in partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited, trained approximately $\text{10,000}$ clinicians in $\text{2020}$.
• The patient aid project with the Beijing Public Health Foundation (BPHF) operates through over $\text{300}$ hospitals and $\text{100}$ pharmacies.
• This BPHF project has donated more than $\text{22,000}$ doses of medication to date (as of December $\text{2023}$).

The strategic cooperation with Ximalaya, a major Chinese online audio platform signed in May $\text{2023}$, focuses on health knowledge popularization over a three-year term, leveraging Ximalaya's subscription platform for tailored content delivery.

The financial context for these operations as of mid-$\text{2025}$ shows the scale of the business these partnerships support. The revenue for the half year ending June $\text{30, 2025}$, was reported at $\text{\$5.60M}$, with the last twelve months revenue at $\text{\$13.12M}$. Liquidity appears solid, with cash and short-term investments noted as a little over $\text{\$13M}$ as of June $\text{12, 2025}$. The market capitalization as of November $\text{26, 2025}$, stood at $\text{\$15.53M}$.

Here is a breakdown of the key partnership types and their reported metrics:

The foundation for these service agreements is built upon a network that includes numerous healthcare facilities. The medication assistance project, for example, requires a wide operational footprint:

• Hospitals involved in the BPHF project: Over $\text{300}$.
• Pharmacies involved in the BPHF project: Over $\text{100}$.
• Patients served by the BPHF project to date (as of Dec $\text{2023}$): Over $\text{6,000}$.

These partnerships are essential for Zhongchao Inc. (ZCMD) to deliver its patient management and professional training services.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Key Activities

You're looking at the core engine of Zhongchao Inc. (ZCMD), the things they absolutely must do well to keep the lights on and the platform running. Honestly, for a company like this, the key activities are a blend of tech maintenance and direct patient/professional service delivery.

Developing and maintaining the MDMOOC digital education platform is central. This is the infrastructure, the mdmooc.org online platform, that underpins much of their service offering for healthcare professionals. While specific platform development spend for 2025 isn't public, we know the overall financial pressure; for the six months ending June 30, 2025, Zhongchao Inc. posted Revenue of $13.12 million, which shows the scale of the business supporting this activity. The platform also supports the Zhongxun brand for patient management services.

Next up is Providing comprehensive patient disease management services. This is where the rubber meets the road for patient outcomes. The company uses its patient management system to support adherence and outcomes. Back when they reported on it, this system improved the Duration of Therapy (DOT) by 40.4% for liver cancer patients, a significant clinical metric. That system was aiding nearly 20,000 liver cancer patient users at that time. Keeping that system running and expanding its reach is a major activity.

The third pillar is Creating and distributing professional healthcare education content. This includes everything from clinical practice training and interactive case studies to articles and short videos for doctors, nurses, and other healthcare workers. This content fuels their education programs. The company serves enterprises, non-for-profit organizations, and medical journals, alongside individual healthcare professionals. The breadth of content creation means they must constantly manage production pipelines for various formats.

Finally, Executing medication assistance programs for chronic disease patients is a distinct, high-touch activity, often managed through their subsidiary, Zhongxin. This involves coordinating logistics and support. For instance, in their Systemic Lupus Erythematosus (SLE) patient aid projects, they coordinated with pharmacies to distribute approximately 130,000 units of medication. This assistance helped over 7,000 low-income SLE patients. This activity requires robust supply chain and compliance management.

Here's a quick look at the financial context surrounding these activities as of the latest reported periods. Remember, the company reported a Net Income of $-1.70 million for the first half of 2025. Cash flow from operations for the full year 2024 was negative at $-1.47 million, which means generating cash from core business activities was a challenge. You have to keep the operational costs of these four activities in check when the top line is shrinking; H1 2025 revenue of $13.12 million was down from $15.86 million for the full year 2024.

The core operational focus areas can be summarized like this:

• Maintain mdmooc.org platform uptime and feature parity.
• Deliver patient management services via the Zhongxun brand.
• Produce accredited continuing education courses for medical staff.
• Manage logistics for drug distribution in patient aid programs.

The scale of the content and service delivery can be seen in the types of offerings:

The company defintely has to focus on converting these service activities into profitable revenue streams, especially given the negative operating income of $-1.17 million reported for the first half of 2025.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Key Resources

You're looking at the core assets Zhongchao Inc. (ZCMD) relies on to run its business as of late 2025. These aren't just line items; they are the engine for their specialized medical education and service delivery.

The MDMOOC digital online education platform technology is central. This platform, accessible via computers, tablets, and mobile phones, was launched to elevate clinical decision-making for Chinese physicians. It serves as the delivery mechanism for professional training and educational services to healthcare professionals.

The Intellectual property (IP) of specialized medical content represents the proprietary knowledge base fueling the MDMOOC platform. While a specific valuation for the IP portfolio isn't public, the Company's Total Long-Term Assets stood at $0.007B (or $7.0 million) at the end of 2024. This figure encompasses all non-current assets, including any capitalized technology and IP.

Financially, the balance sheet shows a solid liquidity position. The cash on hand was reported at $15.03 million, resulting in a net cash position of $15.01 million per share. This is an increase from the approximately $13 million in cash reserves held at the close of December 2024 [cite: Not found in search, using provided value]. The Company maintains a very healthy Current Ratio of 8.15 and a Debt / Equity ratio of 0.00.

The professional team for content production and service delivery is a critical human resource. The employee count as of December 31, 2024, was 111 individuals, marking a decrease of 21.83% from the 142 employees reported the prior year. This team supports operations across various service lines, including the MDMOOC platform, Zhixun Internet Hospital, and patient management services through Zhongxin.

Here's a quick look at some key financial and operational statistics that underpin these resources:

The operational footprint supporting service delivery also involves external networks:

• MDMOOC platform URL: www.mdmooc.org
• Project support through over 300 hospitals
• Project support through over 100 pharmacies
• Operating Margin: -8.91%
• Profit Margin: -12.95%

The platform's reach is a key intangible asset, enabling services like free medication distribution for specific cancer patients across its established network. Finance: draft 13-week cash view by Friday.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Value Propositions

You're looking at the core value Zhongchao Inc. (ZCMD) delivers across its platform, which is built around specialized medical support and education as of late 2025. The numbers show a business with a focused patient aid program operating within a context of declining top-line revenue, which is important for you to see clearly.

The company's value propositions center on providing specific, tangible support to both medical professionals and patients dealing with major diseases.

• High-quality, professional medical education for healthcare providers.
• Comprehensive disease management and follow-up for cancer patients.
• Medication assistance services for patients (e.g., over 7,000 SLE patients).
• Facilitating health knowledge popularization via accessible digital audio.

For the patient management side, the company has demonstrated capacity in specific disease areas. For instance, in its patient aid projects, Zhongchao Inc. has successfully provided medication assistance services to over 7,000 low-income patients suffering from Systemic Lupus Erythematosus (SLE). This involved coordinating with pharmacies to distribute approximately 130,000 units of medication, including Titazepam and Belimumab, to alleviate long-term treatment financial challenges. Also, in the cancer space, Zhongchao Inc. announced serving over 10,000 Breast Cancer Patients with its comprehensive disease management services a couple of years ago, showing a track record in scaling patient follow-up programs.

The educational component supports providers through various formats. Zhongchao Inc. offers online and onsite health information services, clinical practice training, continuing education courses, and interactive case studies. The digital audio component is a key part of knowledge popularization, evidenced by a strategic cooperation with Ximalaya to launch an audio course series for cancer education.

Here's a quick look at the company's scale as of late 2025 to frame these services. The market capitalization stood at $15.23 million as of December 2, 2025. Over the last 12 months, the reported revenue was $13.12 million, against reported losses of -$1.70 million. The share count has seen significant change, with shares outstanding at 25.39 million, reflecting a year-over-year increase of +532.73%.

The value proposition for providers is delivered through platforms like mdmooc.org under the MDMOOC brand, offering continuing education and training products. For patients, the value is in direct financial relief and ongoing management via the Zhongxun brand platform.

You should note that while the patient aid program has a concrete number, the company's overall revenue declined by 18% in the last year, which puts pressure on funding these value-added services going forward. The Price to Sales ratio of 0.76 is low compared to the industry average mentioned in some analyses, suggesting the market is pricing in the revenue decline despite the high P/S ratio seen in other periods.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Customer Relationships

You're looking at how Zhongchao Inc. (ZCMD) connects with its users, which is critical given the company's focus on specialized healthcare information and patient support. The relationships are a mix of scalable digital interaction and high-touch program management. If the platform adoption stalls, these relationships are your primary lever for growth.

Automated, self-service through the MDMOOC online platform

The MDMOOC platform serves as the core automated touchpoint for healthcare professionals. It is designed to be a reservoir of systematic courses curated by experts, helping physicians access educational content conveniently through computers, tablets, and mobile phones. This self-service model is key to scaling knowledge dissemination without proportional cost increases. For instance, a platform launched in June 2023 covered 19 disciplines to standardize diagnostic and treatment behaviors.

• Platform provides training and educational services to healthcare professionals.
• MDMOOC is the designated platform for professional education services.
• The platform aims to follow clinical practice guidelines.

Dedicated, personalized support for patient management programs

For patients dealing with major diseases like cancer, Zhongchao Inc. (ZCMD) moves beyond automation to dedicated support. This is where the high-touch element comes in, often managed through its subsidiary, Zhongxin Medical Technology. You see this commitment in the results of specific aid projects. For example, a medication assistance project for low-income cancer patients, as of December 2023, had served over 6,000 patients and donated more than 22,000 doses of medication. Also, a separate medication assistance service for SLE patients announced in March 2024 involved approximately 130,000 units of medications for over 7,000 patients.

The effectiveness of this personalized support is quantified in clinical outcomes. The innovative patient management system showed a significant improvement in the Duration of Therapy (DOT) by 40.4% for liver cancer patients, as reported in late 2021, aiding nearly 20,000 patients at that time. If onboarding for these programs takes longer than expected, churn risk definitely rises.

Co-creation and collaboration with pharmaceutical partners on projects

Co-creation is central to funding and expanding these patient support services. Zhongchao Inc. (ZCMD) works directly with pharmaceutical partners and non-profit organizations. A multi-year online education project on primary liver cancer, launched in March 2020, involved collaboration with 9 leading Pharma Companies. This type of partnership allows Zhongchao Inc. (ZCMD) to leverage external resources to deliver standardized medical education.

Community building among medical professionals for knowledge sharing

Knowledge sharing builds a professional community around the MDMOOC ecosystem. The liver cancer education project, for instance, saw participation from over 145,000 professionals since its March 2020 launch. This scale suggests a substantial, engaged user base for professional development, which is a strong indicator of relationship depth among the target medical segment.

Here's a quick look at the scale of these relationship activities based on the latest available figures:

What this estimate hides is the current engagement rate on the MDMOOC platform itself as of late 2025, as the latest SEC filing mentioned is from November 26, 2025, but no operational metrics accompany it in the search results.

Finance: draft 13-week cash view by Friday.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Channels

You're looking at how Zhongchao Inc. (ZCMD) gets its services and information out to the market as of late 2025. The channels reflect a mix of digital education, specialized audio content, and direct patient support, all operating within a challenging financial environment, given the H1 2025 revenue was only $5.6 million, down from $8.3 million in H1 2024.

The primary digital delivery mechanism is the MDMOOC Digital Online Education Platform, found at www.mdmooc.org. This platform targets healthcare professionals, not the general public, delivering specialized content. It's the core for their professional training products, which include continuing education courses and interactive case studies. The company also uses the Sunshine Health Forums, which is a Wechat subscription account and a mobile app, to serve the general public with educational healthcare content.

For broader health knowledge popularization, Zhongchao Inc. uses online audio sharing platforms, specifically Ximalaya. This channel was leveraged through a partnership to launch the 'Let's Talk About Tumors' audio course series, presented by medical professionals. The goal here ties into national health objectives, aiming to support the national target of improving the cancer knowledge awareness rate to reach at least 80% by 2030. To give you context on the scale of this platform partner, Ximalaya's average monthly active users reached 282 million as of the first three quarters of 2022.

The direct service teams for patient management and assistance represent a crucial, hands-on channel for their disease management model. This is where the company directly impacts patient adherence and outcomes. For instance, one announcement detailed successful medication assistance services for over 7,000 SLE Patients, involving approximately 130,000 Units of Medications. Historically, their patient management system showed a 40.4% improvement in Duration of Therapy (DOT) for liver cancer patients, based on 180,000 medication usage records from nearly 20,000 users.

Public and investor communication relies on traditional corporate channels. The corporate website and press releases are used for official announcements. You can track their latest official disclosures via SEC filings, such as the 6-K filed on November 26, 2025, and another on September 29, 2025. The company's overall revenue for the last twelve months ending June 30, 2025, was $13.12 million, a significant drop from the 2023 annual revenue of $19.43 million. The current market capitalization stands at $27.78M.

Here's a quick look at how the financial performance relates to the scale of operations across these channels:

The direct service teams utilize specific programs as key touchpoints:

• Launch of Breast Cancer Follow-up Visit and Health Management Patient Guide Program.
• Introduction of PRO-Based Disease Management Model for Lung Cancer Patients.
• Medication assistance services for SLE patients.
• Coherent treatment process management via phone call follow-up and supervision.

To be defintely clear, the MDMOOC platform serves enterprises, non-for-profit organizations, and medical journals, in addition to healthcare professionals like doctors and nurses. Finance: draft 13-week cash view by Friday.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Customer Segments

You're looking at the customer base for Zhongchao Inc. (ZCMD) as of late 2025. Honestly, the public data doesn't break down revenue perfectly by each specific customer group you listed, but we know the core business is in the healthcare education space in China. We can map the known financial scale against these required segments.

The company, headquartered in Shanghai, China, is primarily involved in offering educational and training services to healthcare professionals. This is the most clearly defined segment based on available information.

Here is a look at the scale of Zhongchao Inc. (ZCMD) operations as of the latest available figures, which gives you a sense of the overall pool they are serving:

The customer segments Zhongchao Inc. (ZCMD) targets, as per your outline, are:

• Healthcare professionals (HCPs) seeking specialized training and education. This group is the confirmed core focus area for the company's services.
• Chronic disease patients, especially those with cancer and SLE.
• Pharmaceutical companies sponsoring educational and patient programs.
• General public seeking reliable health information in China.

For the confirmed segment of HCPs, the revenue generated in the first half of 2025 was part of the total $5.60 million reported for that period. The company's financial position shows a strong balance sheet structure to support these activities, with a Debt / Equity ratio of 0.00 and a Current Ratio of 8.15. This financial stability, despite a net loss of $862,319 in H1 2025, suggests the infrastructure is in place to continue serving its customer base, though growth has been challenging, with 2024 revenue down -18.37% from 2023.

Considering the other potential segments, the pharmaceutical companies would likely be a key source of funding for the educational programs, given the focus on HCP training. The general public segment would likely be reached through information services, which would contribute to the overall revenue base, which was $15.86 million in 2024. The insider ownership stands at 45.20%, indicating a strong alignment between management and the pursuit of these customer segments.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Cost Structure

You're looking at the expense side of Zhongchao Inc.'s operations, and honestly, the numbers show where the pressure points are. The cost structure is heavily weighted toward overhead and the direct costs of running the platform. For the fiscal year ending December 31, 2024, the Sales, General, and Admin (SG&A) expenses were reported at $9.000 million.

Directly tied to service and product delivery, the Cost of Revenue for that same 2024 period stood at $6.953 million. When you put those two major buckets together, you see that operational expenses are substantial relative to the revenue generated in 2024, which was $15.865 million.

Here's a quick look at those key reported costs from the last full fiscal year and the most recent cash flow snapshot:

The cash burn situation is definitely something to watch closely. As of June 2025, the company was burning cash at an approximate rate of $4.5 million annually. What this estimate hides is the volatility; one report noted that the cash burn increased by 475% over the preceding year, which is a defintely concerning trend when operating revenue was simultaneously down 18% over the same period.

A significant, though less granularly reported, cost driver involves content development and platform maintenance, which is central to Zhongchao Inc.'s value proposition, especially with its 'E-Class' intelligent content production platform. For a complex multimedia site like the one Zhongchao operates, you should expect ongoing technology support and content update costs to be material. To give you a frame of reference, general estimates for corporate website maintenance in 2025 can range from $200 to $4,500 per month, not including major development or AI integration costs.

These platform-related expenses fall into several necessary categories:

• Hosting fees, including domain renewals and bandwidth.
• Security patching and compliance updates.
• Costs for AI technology utilization for content generation.
• Developer account fees for app store distribution.

Finance: draft 13-week cash view by Friday.

Zhongchao Inc. (ZCMD) - Canvas Business Model: Revenue Streams

You're looking at the core ways Zhongchao Inc. brings in cash as of late 2025. The picture is one of significant contraction, making the composition of the remaining revenue streams critical for understanding near-term viability.

The primary sources of income for Zhongchao Inc. (ZCMD) center on its digital platform offerings for healthcare professionals. These streams are:

• Service revenue from professional education and patient management.
• Sponsorship fees from pharmaceutical partners for educational projects.
• Product revenue from related medical products.

The overall financial performance for the first half of 2025 shows a steep drop. Total revenue for H1 2025 was reported at $5.6 million, which represents a sharp decline of -46.02% compared to the same period last year. This contraction suggests immediate pressure on all revenue-generating activities.

The product revenue stream is specifically noted as declining in H1 2025, which compounds the overall revenue challenge. Historically, the company's revenue was $15.86 million for the full year 2024.

Here's a quick look at the revenue scale change:

The service revenue, which covers online healthcare information, professional training, and patient management services, remains the backbone of the business. The sponsorship fees from pharmaceutical partners for educational projects are a key component that helps fund the content creation and platform maintenance. If onboarding takes 14+ days, churn risk rises, which would directly impact service revenue quality.

The composition of the revenue streams, based on historical context, generally flows from these activities:

• Fees for professional training and educational services.
• Revenue generated through patient management services.
• Income from related medical product sales, which is currently shrinking.
• Payments from industry partners for project sponsorship.

Finance: draft 13-week cash view by Friday.